Workflow
Semtech Corporation (NASDAQ:SMTC) Overview
Financial Modeling Prep· 2025-11-25 06:00
Semtech Corporation's Market Position and Future ProspectsSemtech Corporation (NASDAQ:SMTC) is a mid-cap technology company known for its innovative semiconductor products. It operates in a competitive market alongside other tech firms like LYFT, GTLB, EPAM, and ONTO. These companies are recognized for their strong demand trends and potential for significant brokerage upside, as highlighted by Zacks Investment Research.On November 24, 2025, Morgan Stanley set a price target of $64 for SMTC, while the stock ...
Booking Holdings Inc. (NASDAQ: BKNG) Overview and Financial Outlook
Financial Modeling Prep· 2025-11-25 05:10
BNP Paribas sets a price target of $6,100 for NASDAQ:BKNG, indicating a significant potential upside.The stock has experienced volatility, with a trading range between $4,613.52 and $4,896.32 in a single day.Ewout Steenbergen, CFO, to present at the Nasdaq 53rd Investor Conference, potentially impacting investor sentiment.Booking Holdings Inc. (NASDAQ: BKNG) is a leading player in the online travel industry, providing services through its various brands like Booking.com, Priceline, and Agoda. The company is ...
Novo Nordisk (NYSE:NVO) Downgraded by HSBC Amid Stock Price Decline and Trial Disappointments
Financial Modeling Prep· 2025-11-25 05:04
Novo Nordisk Faces Downgrade and Stock Decline Amid Trial SetbacksHSBC downgrades Novo Nordisk (NYSE:NVO) from "Buy" to "Hold" as the stock nears a four-year low.Significant stock price decline follows disappointing trial data for Alzheimer's drug, semaglutide.Despite the challenges, there is notable activity among call traders, indicating some investor optimism.Novo Nordisk (NYSE:NVO), a leading global healthcare company renowned for its diabetes and obesity treatments, has recently experienced a downgrade ...
Goldman Sachs Initiates Waste Management at Buy, Sets $256 Price Target
Financial Modeling Prep· 2025-11-25 04:58
Goldman Sachs initiated coverage on Waste Management (NYSE: WM) with a Buy rating and a $256 price target. Analysts said they were constructive on the company’s organic growth outlook, forecasting a 7.7% EBITDA CAGR from 2025 to 2027 driven by strong price/cost execution, high-return recycling and landfill-gas investments, and continued synergy capture from the Stericycle acquisition. Goldman noted potential upside tied to improving volumes in Healthcare Solutions (Stericycle) and a recovery in recycled com ...
BNP Paribas Exane Starts Booking Holdings at Outperform With $6,100 Target
Financial Modeling Prep· 2025-11-25 04:58
BNP Paribas Exane initiated coverage on Booking Holdings (NASDAQ: BKNG) with an Outperform rating and a $6,100 price target. The firm said Booking’s industry-leading margin profile and its extensive user base positioned the company to continue investing in international expansion, U.S. market share initiatives, alternative accommodations and artificial-intelligence technologies. Despite elevated investment levels, BNP Paribas expects Booking to grow both market share and earnings. The brokerage projected Bo ...
Carvana Upgraded to Outperform at Wedbush, Shares Gain 7%
Financial Modeling Prep· 2025-11-25 04:57
Wedbush upgraded Carvana (NYSE: CVNA) to Outperform from Neutral and lifted its price target to $400 from $380, driving shares up more than 7% intra-day on Monday. The firm noted that Carvana shares had fallen roughly 13% over the past month, underperforming the S&P 500, largely due to weak near-term results from peer CarMax (KMX) and broader concerns in credit markets. Wedbush argued that the pullback was overdone and created an attractive entry point. Shares now trade around 22x Wedbush’s 2027 EPS estimat ...
Truist Initiates MannKind at Buy on Royalty and Pipeline Growth
Financial Modeling Prep· 2025-11-25 04:49
Truist Securities initiated coverage on MannKind (NASDAQ: MNKD) with a Buy rating and a $9 price target. The firm said it remained encouraged by MannKind’s execution across both commercial and development programs. Its valuation outlook was driven primarily by Tyvaso DPI royalty revenue, with Truist projecting continued growth in idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension associated with interstitial lung disease (PPF) supported by ongoing development and marketing efforts from partner U ...
Deutsche Bank Starts Coverage of Qnity Electronics With Buy Rating and $92 Target
Financial Modeling Prep· 2025-11-25 04:48
Deutsche Bank initiated coverage on Qnity Electronics (NYSE: Q) with a Buy rating and a $92 price target. The brokerage said Qnity Electronics offered a compelling entry point for investors seeking exposure to rapidly expanding materials spending across attractive semiconductor verticals, including leading-edge process nodes and emerging middle-/back-end technologies such as advanced packaging. Approximately 57% of the company’s FY24 sales came from semiconductors, positioning it to benefit from rising mate ...
SentinelOne Price Target Cut at Cantor Fitzgerald, Overweight Rating Maintained
Financial Modeling Prep· 2025-11-25 04:46
Cantor Fitzgerald lowered its price target on SentinelOne Inc. (NYSE: S) to $22 from $24 while reiterating an Overweight rating ahead of the company’s fiscal third-quarter results. The firm said it remained encouraged by strong large-deal momentum, the rollout of the Flex offering, an expanding CNAPP platform supported by the Prompt acquisition, and continued product traction. Analysts added they are watching for signs of improved go-to-market execution, incremental contributions from the Lenovo partnership ...
Regeneron Pharmaceuticals' Stock Performance Amid Market Volatility
Financial Modeling Prep· 2025-11-25 04:03
Truist Financial sets a price target of $798 for Regeneron Pharmaceuticals (NASDAQ:REGN), indicating a potential increase.Regeneron's stock shows resilience with a 1.71% increase despite broader market volatility.The company's significant market capitalization of approximately $79.4 billion underscores its prominence in the biotech industry.Regeneron Pharmaceuticals (NASDAQ:REGN) is a leading biotechnology company known for its innovative medicines. The company focuses on developing treatments for serious d ...